Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun 10;21(1):127.
doi: 10.1186/s12943-022-01602-z.

PRMT7: a survive-or-die switch in cancer stem cells

Christophe Nicot  1
Affiliations
Comment

PRMT7: a survive-or-die switch in cancer stem cells

Christophe Nicot. Mol Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no financial conflict of interest. Christophe Nicot is Editor-in-Chief of Molecular Cancer.

Figures

Fig. 1
Fig. 1
PRMT7 seizes glycine metabolism switch to determine fate of LSCs. A PRMT7 catalyzes H2AR3me2s to inhibit the transcription repressor of TRPS1, eventually upregulating GLDC in CML LSCs. Glycine generated from serine by SHMT2 is converted by GLDC to 5, 10-MTHF, allowing LSCs to gain metabolic addiction. B Genetic deletion or pharmacological inhibition of PRMT7 derepresses the repressor TRPS1, thereby downregulates GLDC and subsequently accumulates intracellular glycine in CML LSCs. Increased intracellular glycine is converted by GCAT to methylglyoxal, which induces the death of CML LSCs
See this image and copyright information in PMC

Comment on

References

    1. Prager BC, Xie Q, Bao S, Rich JN. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell. 2019;24:41–53. doi: 10.1016/j.stem.2018.12.009. - DOI - PMC - PubMed
    1. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–1134. doi: 10.1038/nm.4409. - DOI - PubMed
    1. Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530–542. doi: 10.1016/j.ccell.2020.03.006. - DOI - PMC - PubMed
    1. Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158–173. doi: 10.1038/s41568-019-0230-9. - DOI - PubMed
    1. Liu C, Zou W, Nie D, Li S, Duan C, Zhou M, et al. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell Metab. 2022;S1550-4131(22):00131-0. 10.1016/j.cmet.2022.04.004. Online ahead of print. - PubMed

Substances